OBJECTIVES: To understand relative price differential for cancer drugs in the United States and the United Kingdom. Develop implications for pricing strategy and patient access for cancer drugs. METHODS: Ten branded cancer drugs were selected and their prices for similar dose and packaging were compared in the United States and the United Kingdom. Prices were analyzed for the end of 2011 and early 2012. Historical exchange rates were used to convert British pounds to US dollars. Relative price discount was calculated for all selected cancer drugs. KOLs and payers were interviewed to understand current and future implications of this price differential.  RESULTS: The median price discount for selected ten branded cancer drugs in the United Kingdom versus the Unitted States was ~50%. The range of discount for 10 branded cancer drugs was 27%-61%. The price discount for oral small molecule drugs was higher than for biologics (55% vs. 45%). Since United Kingdom is one of the few remaining free pricing markets in Europe, other European markets are likely to have even higher discounts relative to the prices in the United States. Due to rising coinsurance of speciality products, US cancer patients bear significantly higher cost than patients in the United Kingdom. KOL and payer interviews suggest US pricing trends for cancer drugs are unlikely to be sustained at this level in the future.  CONCLUSIONS: US cancer drug prices are significantly higher than the prices in the United Kingdom. This price differential is unlikely to be sustained in the future.